Abstract
Since the discovery of P-glycoprotein (P-gp) in brain microvessels composing the human blood-brain barrier (BBB), ATPbinding cassette (ABC) transporters have been recognized as bottlenecks in the development and delivery of neuropharmaceuticals. ABC transporters are expressed predominately at the plasma luminal membrane of brain capillary endothelial cells. These ABC transporters are responsible for the efflux of their substrates from the endothelial cells to the bloodstream against the concentration gradient and thus limit the entry of some drugs within the central nervous system (CNS). Advanced quantitative molecular biology tools allowed gene and protein quantification of the components of microvessels isolated from different species including human. Recently, positron emission tomography using radiolabelled probes that are substrates of ABC transporters allowed the determination of their functional activity at the human BBB. Here, we summarized new information regarding the relative expression, substrate recognition pattern for CNS drugs and functional activity of ABC transporters that are quantitatively expressed at the human BBB.
Keywords: ATP-binding cassette transporters, blood-brain barrier, blood-cerebrospinal fluid barrier, P-glycoprotein, breast cancer resistance protein, multidrug resistance protein.
Current Pharmaceutical Design
Title:Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Volume: 20 Issue: 10
Author(s): Catarina Chaves, Ramzi Shawahna, Aude Jacob, Jean-Michel Scherrmann and Xavier Declèves*
Affiliation:
- Neuropsychopharmacologie des addictions (CNRS UMR 8206), Université Paris Descartes, Faculté de Pharmacie, Paris,France
Keywords: ATP-binding cassette transporters, blood-brain barrier, blood-cerebrospinal fluid barrier, P-glycoprotein, breast cancer resistance protein, multidrug resistance protein.
Abstract: Since the discovery of P-glycoprotein (P-gp) in brain microvessels composing the human blood-brain barrier (BBB), ATPbinding cassette (ABC) transporters have been recognized as bottlenecks in the development and delivery of neuropharmaceuticals. ABC transporters are expressed predominately at the plasma luminal membrane of brain capillary endothelial cells. These ABC transporters are responsible for the efflux of their substrates from the endothelial cells to the bloodstream against the concentration gradient and thus limit the entry of some drugs within the central nervous system (CNS). Advanced quantitative molecular biology tools allowed gene and protein quantification of the components of microvessels isolated from different species including human. Recently, positron emission tomography using radiolabelled probes that are substrates of ABC transporters allowed the determination of their functional activity at the human BBB. Here, we summarized new information regarding the relative expression, substrate recognition pattern for CNS drugs and functional activity of ABC transporters that are quantitatively expressed at the human BBB.
Export Options
About this article
Cite this article as:
Chaves Catarina, Shawahna Ramzi, Jacob Aude, Scherrmann Jean-Michel and Declèves Xavier*, Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990466
DOI https://dx.doi.org/10.2174/13816128113199990466 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery and Applications of Disulfide-Rich Cyclic Peptides
Current Topics in Medicinal Chemistry Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Stationary Wavelet Transform and AdaBoost with SVM Based Pathological Brain Detection in MRI Scanning
CNS & Neurological Disorders - Drug Targets Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Validated Mathematical Model of Tumour-Immune Interactions for Glioblastoma
Current Medical Imaging Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Cellomics as Integrative Omics for Cancer
Current Proteomics